https://www.biospace.com/press-releases/verastem-oncology-announces-75-million-private-placement
Verastem Oncology Announces $75 million Private Placement - BioSpace
verastem oncologyprivate placementannounces75million
https://www.biospace.com/verastem-oncology-announces-reverse-stock-split-may-31-2023
Verastem Oncology Announces Reverse Stock Split - May 31, 2023 - BioSpace
Jun 1, 2023 - Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that it will effect a 1-for-12 reverse...
reverse stock splitmay 31 2023verastem oncologyannounces
https://www.businesswire.com/news/home/20260402851535/en/Verastem-Oncology-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today a...
verastem oncology
https://www.businesswire.com/news/home/20210120005098/en/Frank-Neumann-M.D.-Ph.D.-to-Depart-Verastem-Oncology
Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer...
m dfrankneumannphdepart
https://www.biospace.com/verastem-oncology-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-april-4-2024
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4, 2024...
Apr 4, 2024 - Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock...
https://www.biospace.com/verastem-oncology-to-present-at-the-rbc-capital-markets-global-healthcare-conference
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference - BioSpace
May 8, 2024 - Verastem Oncology announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New...
rbc capital markets
https://www.biospace.com/press-releases/verastem-oncology-announces-u-s-ind-clearance-of-vs-7375-oral-kras-g12d-on-off-inhibitor-enabling-phase-1-2a-trial-in-advanced-solid-tumors
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor,...